Pinder R M, Brogden R N, Swayer R, Speight T M, Spencer R, Avery G S
Drugs. 1976;12(1):1-40. doi: 10.2165/00003495-197612010-00001.
Pimozide 1-(1-[4,4-bis(4-fluorophenyl)butyl]-4-peperidinyl)-2-benzimidazolone, is the first of a new series of psychotropic drugs, the kiphenylbutylpiperidines. It is advocated for once-daily use as maintenance therapy in chronic schizophrenia and for the treatment of psychic and functional disorders induced by personality traits. Published data suggest that in chronic schizophrenia, pimozide 4 to 6mg daily is indistinguishable from maintenance doses of chlorpromazine, fluphenazine, flupenthixol, perphenazine, or thioidazine. Patient groups have usually been to small to allow statistically significant differences to be apparent, but in some trials pimozide was significantly superior to trifluoperzine and to haloperidol. On present evidence, pimozide has no place in the hyperactive, aggressive type of patient or in treating the acute phase of schizophrenia, probably because of its relative lack of sedative properties compared with many antipsychotic drugs. The incidence and severity of extrapyramidal reactions with pimozide are low, but suitably designed controlled studies are needed to determine whether its use leads to a reduction in the requirement for antiparkinsonian medication. In anxious patients, pimozide seems to offer no advantages over currently available anxiolytic agents, either in terms of efficacy or incidence of side-effects. Claims for a specific effect against anxiety associated with psychosis or disturbed personality traits remain unproven.
匹莫齐特1-(1-[4,4-双(4-氟苯基)丁基]-4-哌啶基)-2-苯并咪唑酮，是一类新型精神药物——联苯基丁基哌啶类中的首个药物。它被推荐用于慢性精神分裂症的每日一次维持治疗以及治疗由人格特质引起的精神和功能障碍。已发表的数据表明，在慢性精神分裂症中，每日4至6毫克的匹莫齐特与氯丙嗪、氟奋乃静、氟哌噻吨、奋乃静或硫利达嗪的维持剂量效果相当。患者群体通常规模较小，难以显现出具有统计学意义的差异，但在一些试验中，匹莫齐特显著优于三氟拉嗪和氟哌啶醇。根据目前的证据，匹莫齐特在治疗多动、攻击性类型的患者或精神分裂症急性期方面并无用武之地，这可能是因为与许多抗精神病药物相比，它相对缺乏镇静作用。匹莫齐特引起锥体外系反应的发生率和严重程度较低，但需要进行设计合理的对照研究，以确定其使用是否会减少抗帕金森药物的需求。在焦虑患者中，无论是在疗效还是副作用发生率方面，匹莫齐特似乎都不比现有的抗焦虑药物更具优势。关于其对与精神病或人格特质紊乱相关的焦虑有特效的说法尚未得到证实。
